Mark Trudeau is the president and chief executive officer of Mallinckrodt Pharmaceuticals.   

Mr. Trudeau was formerly President of the pharmaceuticals business of Covidien, with experience in markets around the world. Originally from Detroit, Michigan, he has lived and worked in Singapore, Canada, and the United Kingdom, as well as in the United States.  

Prior to his tenure at Covidien, Mr. Trudeau served as President and CEO of Bayer HealthCare Pharmaceuticals Inc. He simultaneously served as interim President of the global specialty medicine business unit from January to August 2010.  

Before joining Bayer in 2009, Mr. Trudeau headed the immunoscience division at Bristol-Myers Squibb. During his more than 10 years there, he served in multiple senior roles, including as President of the Asia/Pacific region, President and general manager of Canada operations, and General Manager and Managing Director of UK operations. Mr. Trudeau was previously with Abbott Laboratories, serving in a variety of executive positions. He began his career in engineering at Eli Lilly and Company and at E.I. DuPont De Nemours, Inc.  

Mr. Trudeau holds a bachelor’s degree in chemical engineering and a master’s degree in business administration, both from the University of Michigan.